Trinomab demonstrates the confidence of China’s biopharmaceutical brands through its innovative fully human monoclonal antibodies.

As the 10th “China Brand Day” approaches on May 10, 2026, People's Daily Online has launched a special feature dedicated to “China Brand Day,” aiming to bolster China’s powerful brands and enhance the country’s global image. Zhuhai Trinomab Biopharmaceutical Co., Ltd. (hereafter referred to as "Trinomab") has successfully showcased its presence at this year’s “China Brand Day” event, thanks to its globally pioneering innovations in the field of fully human monoclonal antibodies, thereby highlighting the robust strength and brand value of China’s innovative biopharmaceutical companies.

01 China Brand Day: Ten Years of Building the Rise of National Brands

Since its establishment officially approved by the State Council in 2017, China Brand Day has now reached its 10-year milstone. As a national-level brand event initiative, it has long been guided by the vision of “transforming Made in China to Created in China, Chinese speed to Chinese quality, and Chinese products to Chinese brands”. It serves as an authoritative platform for independent brands to display their strengths, exchange their insights, draw inspiration from one another, raise public brand awareness and empower high-quality economic development. At this decade-marked juncture, China Brand Day has evolved into an important window for observing the development direction of New Quality Productive Forces and building industrial brand consensus. Trinomab’s includion in People’s Daily Online’s special coverage aligns deeply with the core propositions of China Brand Day across six dimensions: technology, product, industry, globalization, capital and ecosystem, jointly delivering the vision of “Chinese Brands, Healthy China”.

02 Technology Brand: Defining Chinese Brands Through Original Innovation

Trinomab is dedicated to the development, manufacturing, commercialization of fully human monoclonal antibody therapeutics, as well as the potential substitution of globally specific blood products, in order to meet a wide range of clinical needs and benefit patients. The company has always been guided by the mission of “creating clinical value.” After ten years of deep cultivation, Trinomab has transformed from an early-stage R&D-focused biotechnology enterprise into an innovative biopharmaceutical company with complete industrialization capabilities. Its core competitiveness stems from its independently developed, high-throughput, comprehensive technology platform for fully human monoclonal antibody discovery—HitmAb. This technological foundation endows the company with original innovation capabilities and has imbued the “Trinomab” brand, since its inception, with a strong “hard-tech” identity.

03 Product Brand: Gaining Patient Trust Through Clinical Value

Trinomab’s core product—the next-generation “tetanus shot,” Siltartoxatug Injection is the world’s first recombinant, fully human monoclonal antibody against tetanus toxin. This drug completely breaks away from the traditional reliance on human- or horse-derived products for tetanus shots, offering groundbreaking advantages such as “no skin test required, single injection administration, rapid onset of action, and a protection period lasting up to 90 days.” It thus ushers in a revolutionary shift, ending the century-old outdated paradigm of conventional passive immunization agents for tetanus. In December 2025, Siltartoxatug Injection was successfully included in the “National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List (2025)” and will be uniformly implemented nationwide starting January 1, 2026, achieving the efficient realization of “innovative drugs entering insurance coverage immediately upon launch.”

While accelerating the development of a tiered product pipeline, the company’s other key investigational product—a recombinant fully human monoclonal antibody against respiratory syncytial virus (RSV)—Retavibart Monoclonal Antibody Injection, has also been filed for new drug application in February 2026 and has been granted for priority review. This promising therapy is expected to provide safe, convenient, and long-lasting immune protection against RSV infection for infants in China and around the world throughout the RSV epidemic season, thereby helping safeguard children’s health. From “good medicine” to “excellent medicine,” the strength of our product brands has always been measured by clinical value. Echoing the core theme of Brand Day—“meeting the people’s needs for a better life.”

04 Industry Brand: Deeply cultivate the Greater Bay Area and enhance local brand recognition.

“China Brand Day” not only serves as a test for companies’ core strengths but also empowers local industrial clusters. Trinomab, rooted in Zhuhai, has built an antibody production base that meets international GMP standards and boasts end-to-end capabilities—from molecule discovery to large-scale manufacturing—positioning itself as a rising force in the biopharmaceutical industry chain of the Guangdong-Hong Kong-Macao Greater Bay Area. By showcasing its presence in the special feature on People’s Daily Online’s Brand Day, Trinomab is further enhancing the reputation of “Made in Zhuhai” and “Made in Guangdong” biopharmaceuticals, attracting top-tier talent, upstream and downstream enterprises, and public platforms to converge in the Greater Bay Area. This will drive the branding upgrade of Zhuhai’s biopharmaceutical sector and, through the strength of corporate brands, help establish Zhuhai as a prominent industrial hub for the city.

05 International Brands: From “China’s New” to “Global New”

A brand’s influence depends on its ability to compete globally. As a world-first innovation, Siltartoxatug Injection has ushered in a new era of tetanus passive immunization. Research results of the phase III clinical trial study of siltartoxatug have been published in Nature Medicine (Impact Factor: 50.0), signifying that clinical evidence of China’s innovative drugs has been recognized by top international academic communities. Meanwhile, Trinomab’s fully human anti-RSV monoclonal antibody targets the global imperative of infant prevention, aiming to break the monopoly of imported products and provide a “Chinese solution” for the global market. With the spotlight of China Brand Day, Trinomab is accelerating overseas clinical registrations and commercial layout, driving China’s innovative biologic brands from domestic renown to international recognition, and enabling “Smart Manufacturing in China” monoclonal antibody drugs to benefit patients worldwide.

06 Capital and Eco-Brands: Industry-Finance Interaction to Jointly Build an Innovation Hub

The listing committee of the STAR Market at the stock exchange has passed the review on the application for listing. This vote of confidence from investors not only validates the long-term value of the company’s core technology but also marks a new stage in which the Trinomab brand is entering the public spotlight. Building on this foundation, the company is actively pursue an innovative collaborative ecosystem that integrates industry, academia and research institutions, thereby creating a symbiotic and mutually beneficial brand effect.

From “Made in China” to “Smartly Made in China,” Trinomab is writing a new chapter for the “China Brand, Healthy China” era through its original technologies, world-first innovations, clinical value, and international recognition. Looking ahead, Trinomab will continue to deepen its expertise in the field of fully human monoclonal antibodies, accelerate the R&D and commercialization of its key pipeline programs, and, fueled by relentless innovation, safeguard the health of patients worldwide while contributing to the realization of the “Healthy China 2030” initiative and the high-quality development of the biopharmaceutical industry.